A comparison between the use of recombinant hirudin and heparin during hemodialysis.

[1]  J. Piper.  The fate of heparin in rabbits after intravenous injection; filtration and tubular secretion in the kidneys. , 2009, Acta pharmacologica et toxicologica.

[2]  J. Soria,et al.  Recombinant hirudin: a specific thrombin inhibiting anticoagulant for hemodialysis. , 1994, Kidney international.

[3]  Frame Jn.  Approach to bleeding disorders. , 1994 .

[4]  F. Markwardt,et al.  Pharmacology of r-hirudin in renal impairment. , 1992, Thrombosis research.

[5]  H. Groetsch,et al.  Comparison of two different methods for the determination of rDNA-hirudin in plasma samples: HPLC vs a chromogenic thrombin substrate. , 1991, Thrombosis research.

[6]  F. Markwardt.  Hirudin and Derivatives as Anticoagulant Agents , 1991, Thrombosis and Haemostasis.

[7]  F. Markwardt.  Past, present and future of hirudin. , 1991, Haemostasis.

[8]  D. Hoppensteadt,et al.  Comparative Studies on Various Assays for the Laboratory Evaluation of r-Hirudin , 1991, Seminars in thrombosis and hemostasis.

[9]  S. Hanson,et al.  Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. , 1991, Blood.

[10]  F. Markwardt,et al.  Hirudin in haemodialysis. , 1990, Thrombosis research.

[11]  V. Armstrong,et al.  Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis. , 1990, Seminars in thrombosis and hemostasis.

[12]  T. Akizawa,et al.  Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan. , 1990, Seminars in thrombosis and hemostasis.

[13]  P. Badenhorst,et al.  The pharmacology of recombinant hirudin, a new anticoagulant. , 1990, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[14]  V. Wyk,et al.  Low molecular weight heparin as an anticoagulant for in vitro platelet funtion studies , 1990 .

[15]  L. Henderson,et al.  Prevention of heparin-resistant thrombotic occlusion of hollow-fiber hemodialyzers by synthetic antithrombin. , 1989, The Journal of laboratory and clinical medicine.

[16]  J. Hoffmann,et al.  Automated nephelometry of fibrinogen: analytical performance and observations during thrombolytic therapy. , 1988, Clinical chemistry.

[17]  S. Hanson,et al.  Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Schoen,et al.  The in situ inhibition of prothrombinase-formed human alpha-thrombin and meizothrombin(des F1) by antithrombin III and heparin. , 1987, The Journal of biological chemistry.

[19]  L V McIntire,et al.  Platelet active concentration profiles near growing thrombi. A mathematical consideration. , 1986, Biophysical journal.

[20]  G. Stöffler,et al.  Quantitative enzyme-linked immunosorbent assay (ELISA) for hirudin. , 1986, JIM - Journal of Immunological Methods.

[21]  J. Courtney,et al.  A Modification of the Wu and Hoak Method for the Determination of Platelet Aggregates and Platelet Adhesion , 1985, Thrombosis and Haemostasis.

[22]  D. Lane,et al.  Anticoagulant activities of heparin oligosaccharides and their neutralization by platelet factor 4. , 1984, The Biochemical journal.

[23]  F. Markwardt,et al.  Pharmacological Studies on the Antithrombotic Action of Hirudin in Experimental Animals , 1982, Thrombosis and Haemostasis.

[24]  W. Clark,et al.  Platelet Destruction in Renal Disease , 1982, Seminars in thrombosis and hemostasis.

[25]  J. Takeuchi,et al.  The role of heparin in the changes of lipid patterns during a single hemodialysis. , 1982, Clinical nephrology.

[26]  A. Schreiber,et al.  Heparin-associated thrombocytopenia. , 1980, The New England journal of medicine.

[27]  S. Gitel,et al.  Heparin: new concepts relevant to clinical use. , 1979, Blood.

[28]  M. L. Larsen,et al.  Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). , 1978, Thrombosis research.

[29]  Vogel Ge,et al.  The conflict between anticoagulation and hemostasis during hemodialysis. , 1978 .

[30]  R. Rosenberg,et al.  The purification and mechanism of action of human antithrombin-heparin cofactor. , 1973, The Journal of biological chemistry.

[31]  J. Bichler,et al.  Studies for revealing a possible sensitization to hirudin after repeated intravenous injections in baboons. , 1991, Thrombosis research.

[32]  J. Roodt,et al.  Comparison of oxine and tropolone methods for labeling human platelets with indium-111. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  F. Markwardt,et al.  Pharmacokinetic studies with recombinant hirudin in dogs. , 1988, Folia haematologica.

[34]  F. Markwardt,et al.  Studies on the pharmacokinetics of hirudin. , 1987, Biomedica biochimica acta.

[35]  S. Mohammad,et al.  Extracorporeal Thrombogenesis: Mechanisms and Prevention , 1983 .

[36]  R. Swartz.  Hemorrhage during high-risk hemodialysis using controlled heparinization. , 1981, Nephron.

[37]  R. Rosenberg,et al.  Effect of heparin and heparin fractions on platelet aggregation. , 1980, The Journal of clinical investigation.

[38]  R. Rosenberg.  Heparin, antithrombin, and abnormal clotting. , 1978, Annual review of medicine.